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Case ReportReverse vertical transmission of hepatitis B virus (HBV)
infection from a transfusion-infected newborn to her mother
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Service SRC Central Switzerland, Lucerne, Switzerland; 4Department of Haematology, University of Cambridge, Cambridge, UKBackground & Aims: Clinical cases of viral infections possibly and intra-familial, sexual both hetero and homosexual, and
involving the transfusion of blood components are systematically
investigated.
Methods: Serological and molecular markers of hepatitis B virus
were used including HBsAg, anti-HBc, anti-HBs, HBV DNA, and
viral load. Full genome sequencing and phylogenetic analyses
were performed.
Results: An acute HBV infection was diagnosed in the mother of a
16-month-old daughter who had been transfused at age three
weeks with one quarter of a regular red cell concentrate (RCC).
The repeat donor of the index donation was free of HBV markers
in two previous donations but seroconverted to anti-HBc and
anti-HBs 3 months post-donation of a unit containing only low
level of HBV DNA. One other newborn recipient of the same
RCC was asymptomatically HBV infected. A third newborn recipi-
ent whose mother had been HBV vaccinated and carried moder-
ate level of anti-HBs was not infected. Full length nucleotide
sequence identity between HBV strains from the mother and
the two infected transfusion recipients provided evidence of the
transfusion origin of all three infections in the absence of donor
sequence.
Conclusions: Reverse vertical HBV transmission was likely the
result of casual mother contact with a baby carrying extremely
high viral load. The blood products intended to immunodeﬁcient
newborn should be submitted to more thorough viral testing
considering their increased susceptibility to infections.
 2011 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Hepatitis B infection natural history has recognized a large num-
ber of possible routes of transmission including vertical from
infected mother to child, horizontal between young childrenJournal of Hepatology 20
Keywords: Hepatitis B virus; Transfusion; Newborn; Familial transmission.
Received 27 June 2011; received in revised form 7 July 2011; accepted 7 July 2011
⇑ Corresponding author. Address: Blood Transfusion Service SRC Berne, Mur-
tenstrasse 133, 3008 Berne, Switzerland. Tel.: +41 31 384 23 04.
E-mail address: christoph.niederhauser@bsd-be.ch (C. Niederhauser).
Abbreviations: HBV, hepatitis B virus; RCC, red cell concentrate; NAT, nucleic acid
testing; WP, window period.
Open access under CC BY-NC-ND license.through direct blood contact including blood transfusion. To
our knowledge, reverse vertical transmission from an externally
infected infant to the mother, has not been described. Factors pri-
marily involved in HBV infectivity are, on the virus side, viral load
and, in the presence of neutralizing antibodies such as anti-HBs,
the selection of infectious escape mutants. On the host side, deﬁ-
cient immune system, whether congenitally or acquired such as
with HIV infection, drug induced such as in organ transplanta-
tion, or naturally in newborn and infants, was shown to affect
the infectious dose being lower, and the natural history by the
establishment of chronic infection [1].
In a blood transfusion context, evidence of the shortcomings
of screening for the surface antigen, even with the recent most
sensitive HBsAg assays, was provided to a little extent clinically
but more recently by the introduction of nucleic acid testing
(NAT) of blood donations. This approach has identiﬁed donors
donating blood during the pre-seroconversion window period
(WP) or during a late stage of the infection natural history called
occult HBV infection or OBI characterized by low viral load, no
detectable HBsAg, and usually anti-HBc associated or not with
anti-HBs [2]. It was clearly shown that in the WP, the virus pro-
duced in the absence of antibodies was extremely infectious (<10
copies) while OBI infectivity was substantially reduced unless in
immunodeﬁcient hosts [3].Materials and methods
Case history
In June 2009 a 40-year-old woman not vaccinated to HBV presented with a clin-
ically acute hepatitis. HBsAg, anti-HBc IgG and IgM, and anti-HBe were positive,
conﬁrming a suspected HBV etiology. The viral load was 2.5  105 IU/ml and
the alanine aminotransferase level (ALT, Cobas Integra 400, Roche Diagnostics,
Rotkreuz, Switzerland) was 2924 IU/l. To determine the origin of this infection,
a family investigation was initiated. Both husband and son presented no clinical
or serological evidence of HBV infection. However, the 16-month-old daughter
was positive for HBsAg and anti-HBc IgG and had a viral load of 1.6  109 IU/
ml. This unexpected discovery in an otherwise clinically healthy baby triggered
an investigation leading to the identiﬁcation of a red cell concentrate transfusion
performed three weeks after birth on March 8th, 2009.
The donation collected on February 2nd, 2009 was negative for HBsAg and
was not tested for either anti-HBc or HBV DNA. The blood had been processed
into a quadruple split of red cell concentrates. In addition to the index baby girl,12 vol. 56 j 734–737
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these blood donation subunits were transfused to two other infant recipients on
March 10th (Recipient 2) and 14th (Recipient 3), respectively. The fourth split
concentrate was not transfused and discarded when outdated. Retrospective clin-
ical and laboratory examination of these two recipients at age 18 months uncov-
ered the presence of HBsAg, low level anti-HBc and 4.0  103 IU/ml of HBV DNA
in Recipient 2 but an absence of HBV markers in Recipient 3. The mother of Reci-
pient 2 did not consent to investigations but the mother of Recipient 3 had been
vaccinated to HBV in June 2006, received 2 boosting injections in October 2006
and March 2007, respectively and carried 295 IU/ml of anti-HBs in February
2011, 24 months after delivery.
Samples examined
Plasma donor samples at index, three post-donation and two pre-donation dates
were available. Two post-transfusion plasma samples from Recipient 1 and one
sample from each Recipients 2 and 3, collected between June and October
2010, were available. Two plasma samples from the mother of Recipient 1 and
one sample from mother of Recipient 3 were collected in June 2010. Other sam-
ples were collected from several family members but did not carry any HBV
markers.
HBV testing
HBsAg was tested initially with the Architect i2000SR assay (Abbott AG, Diagnos-
tics Division, Baar, Switzerland). Conﬁrmation was done by alternative assays:
Elecsys (Roche, Rotkreuz, Switzerland) and Axsym (Abbott, Delkenheim, Ger-
many). HBeAg, anti-HBc IgM, anti-HBe, anti-HBc total and quantitative anti-HBs
were also tested with both Elecsys and Axsym, as previously described [4].
As sample volume permitted, HBV DNA presence and load were tested with
the Abbott Real-Time HBV Assay (Abbott, Delkenheim, Germany), the Cobas
Amplicor HBV Monitor (Roche Diagnostics, Rotkreuz, Switzerland) and an in-
house real-time PCR in the Cambridge laboratory [5]. Genotyping was performed
with the INNO-LiPA HBV Genotype Assay (Innogenetics, Ghent, Belgium) and by
phylogenetic analysis of the whole genome, as previously described [6]. HBV
strains from the two infected infants and the infected mother of Recipient 1 were
sequenced for the HBV regions S, Pre-S/S and the whole HBV genome minus 50
nucleotide of the BCP/PC.ALT 2942 IU/L ALT n.d.n.d.
Fig. 1. General summary of the case. Dates on top of each box indicate the time
of sample collection. The ﬂow chart goes logically from infected blood donation to
recipients to mother of Recipients 1 and Recipient 2, although the ﬂow of HBV
infection discovery went in the reverse order. n.d., test not done; ± indicates weak
signal in the grey zone of the assay; ALT, alanine amino transferase is expressed in
IU/l. HBV DNA level is expressed in IU/ml and anti-HBs level is expressed in IU/L.Results
The results of the HBV marker investigations in all individuals
involved in this case are presented in Fig. 1. The donor details
are presented in Table 1. The donor presented low level of HBV
DNA but no HBsAg at the time of the index donation. A previous
donation taken 4 months before was negative for all markers of
HBV, in particular anti-HBc was retrospectively found negative.
Three, nine and 10 months after index donation, anti-HBc and
high levels of anti-HBs were found, a pattern compatible with
recent HBV infection, the index donation being in the window
period.
The three recipients of the index donation were retrieved and
tested for HBV markers. Recipient 1 was tested twice, at two-
week interval at age 17 months. The presence of 1.6  109
IU/ml viral load, HBsAg and anti-HBc 16 months after transfusion
with normal ALT level suggests an HBV chronic infection
established in an infant with immature immune system. Recipi-
ent 2 is most likely in the same situation although a slightly ele-
vated ALT level of 60 IU/L was found. In contrast, Recipient 3,
although exposed to the same blood at 2 weeks of age, did not
carry markers of HBV infection 20 months after transfusion. None
of these infants presented symptoms related to hepatitis virus
infection although Recipient 1 presented several weeks of diar-
rhea at age 1 year and an oozing tear of the anal region.
The mother of Recipient 1 was the trigger of the investigation
by developing an acute hepatitis B identiﬁed 16 months after
delivering her last child. The infection was conﬁrmed by highJournal of Hepatology 201level of ALT, high viral load, positive anti-HBc, and declining
HBsAg. In order to determine whether the donor was the
potential origin of the three infections (Recipient 1 and his
mother, Recipient 2), full genome sequencing of HBV was per-
formed separately for each sample in order to exclude the risk
of laboratory cross-contamination. As shown in Fig. 2, all three
strains were genotype A2 and identical. The amino acid
sequences of the pre-S/S proteins and of the major hydrophilic
region were identical to the consensus sequence of the sub-geno-
type indicating wild type strains. Direct evidence of a common
blood donation origin could not be obtained since no blood donor
material was available. However, the identity of nucleotide
sequence between the two unrelated recipients living in distant
Swiss towns strongly suggests such relationship.
Evidence that an upstream infection from baby to mother
occurred was investigated. She did not breast feed at any
time. The acute clinical maternal infection occurring 16 months
after delivery suggested an infection when the infant was
13–14 months. At that time, the mother reports that the infant
had diarrhea occasionally streaked with blood. The mother
noticed that she had very dry skin with small crevices but she
did not wear gloves when taking care of her baby.2 vol. 56 j 734–737 735
Table 1. Donor data in index, pre- and post-index transfusion samples.
Donor Index donation
Date 09.06.08 15.10.08 02.02.09 22.05.09 26.11.09 14.04.10
HBsAg screening Negative Negative Negative Negative Negative Negative
HBV NAT screening n.d.2 n.d. n.d. n.d. Negative1 Negative1
Anti-HBc IgG/IgM Negative Negative n.d. Positive Positive Positive
Anti-HBs (IU/L) Negative Negative n.d. >1000 >1000 >1000 
Anti-HBe n.d. n.d. n.d. n.d. n.d. Positive
HBV DNA quantitative n.d. n.d. 253 IU/ml n.d. n.d. n.d.
1HBV NAT screening in pools of six samples with the Roche s201 system was instituted in September 2009.
2n.d., not done.
Case ReportThe mother of Recipient 3 had been vaccinated to HBV and,
when tested in February 2011 when the child was 24-month-
old, her anti-HBs level was 295 IU/L, more than 3.5 years after a
vaccine boosting injection.Discussion
The interpretation of the data collected on this extraordinary case
is of an adult, asymptomatic, blood donor whose split red cell
concentrate transmitted HBV to two susceptible recipients, one
of them infecting her mother whose clinical expression of the
infection triggered an investigation leading to the discovery of
asymptomatic chronic infections in two immunodeﬁcient infants
and a recovered asymptomatic infection in an immunocompetent
adult (Fig. 1). In the absence of a donor HBV sequence due to lack
of available sample from the incriminated blood donation, this
scenario is only supported by the identity of sequences between
two silently infected unconnected newborns (Fig. 2). This identity
extended to the sequence obtained from the mother of newborn
Recipient 1, virtually excluding a laboratory contamination from
Recipient 2 to Recipient 1. Nosocomial infection can be excluded
by the fact that both babies were hospitalized in different hospi-
tals, the only link between the two being the transfusion of one
third of the index blood unit. The third baby, Recipient 3, was
not infected although receiving the same amount of blood con-
taining approximately 5 ml of plasma. His mother had been vac-
cinated to HBV and carried 295 IU/ml of anti-HBs 24 months after
delivery suggesting 300–400 IU/L at the time of delivery.
Although her child did not carry detectable levels of anti-HBs at
age 20 months (Fig. 1), the presence of approximately the same
level of passively acquired antibodies from his mother anti-HBs
at the time of transfusion [7] was effective to prevent infection
from low titer HBV (1500 IU infectious dose). Vaccine-induced
IgG 1 and 3 are readily transferred to the fetus during the last tri-
mester of pregnancy [8].
The trigger of this investigation was the symptomatic acute
HBV infection of Recipient 1 whose virus Pre-S/S sequence was
identical to her transfused daughter, strongly suggesting daugh-
ter to mother infection. Considering the 16-month interval
between the likely transfusion-related infection of the newborn
daughter and the mother acute HBV infection, it is likely that
the transmission took place 13–14 month after delivery when
the HBV load of the daughter was at least as high as it was when736 Journal of Hepatology 201quantiﬁed at age 17 months (1.9  109 IU/ml). This mother did
not breastfeed at any time but took care of her baby. She reported
that when her daughter was approximately 1 year old (winter
2009–2010) she presented dry skin and crevices of her hands. It
has been previously reported that saliva and urine from chronic
HBV infected individuals contain viral DNA and can be infectious
[9–13]. Saliva was likely partially contaminated with serum
when the child’s teeth were coming out and saliva exchange
might have taken place during kissing. Changing urine-contami-
nated nappies without gloves protecting breached skin might be
an alternative, although less likely, route of infection. The main
factor in this case is the extremely high viral load observed in a
baby infected during a period of relative immunodeﬁciency fol-
lowing birth.
The evidence supporting the reality of this series of infec-
tions originating from the blood donor, although indirect, is
rather strong. In addition to the patients’ HBV sequence identity
indicated above, the pattern of absence of HBV markers in sam-
ples taken 9 and 4 months prior to the index donation, low level
HBV DNA without detectable HBsAg in the index donation, fol-
lowed 100 days later by the presence of anti-HBc and high level
of anti-HBs strongly suggest the occurrence of an asymptomatic
acute infection followed by full recovery; the index donation
corresponding to the early stages of the window period (Table
1). Upon questioning, however, the donor denied any risk fac-
tors, such has sexual activity with a known carrier of HBV, pro-
miscuous homo- or heterosexual behavior, tattooing or skin
piercing.
This report illustrates several important points regarding
HBV epidemiology. Low levels of HBV DNA, particularly during
the window period, are highly infectious especially by
transfusion received by immunodeﬁcient infants. The system-
atic testing of HBV DNA recently instituted nationwide in Swit-
zerland should therefore prevent the occurrence of such
infections [3]. Red cell concentrates split for pediatric use
should be the object of special safety measures including single
unit nucleic acid testing. The infectivity of blood or body ﬂuids
from HBV infected infants or young children is high in propor-
tion to their extremely high viral load, explaining the high
level of horizontal transmission observed in sub-Saharan Africa
[14,15]. The same mechanisms here applied to a caring mother.
Low levels of vaccine-acquired, transmitted through placenta,
anti-HBs have been protective of low level though highly infec-
tious HBV.2 vol. 56 j 734–737
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Fig. 2. Phylogenetic tree of the HBV full genome of three related infections.
The Pre-S/S region sequenced includes 1190 nucleotides. 10,501, 10,255, and
10,499 correspond to the sequences of Recipient 1, her mother and Recipient 2,
respectively. GenBank accession number followed by the hyphenated genotype
identiﬁes the reference sequences. The numbers on top of bars indicate the
bootstrap value.
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